Caribou Biosciences (CRBU) Cash & Current Investments (2020 - 2026)

Caribou Biosciences (CRBU) has reported Cash & Current Investments for 7 consecutive years, with $117.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 43.58% year-over-year to $117.6 million; the TTM figure through Mar 2026 stood at $117.6 million (down 43.58% YoY), while the FY2025 annual figure was $139.3 million, down 33.5% from the prior year.
• Cash & Current Investments slipped to $117.6 million in Q1 2026 per CRBU's latest filing, from $139.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $353.7 million in Q1 2022 and bottomed at $117.6 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $245.9 million across 5 years, with a median of $247.7 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments surged 162.44% — and 2026, when it sank 43.58%.
• Caribou Biosciences' Cash & Current Investments stood at $247.7 million in 2022, then jumped by 32.77% to $328.8 million in 2023, then plunged by 36.28% to $209.5 million in 2024, then slumped by 33.5% to $139.3 million in 2025, then dropped by 15.58% to $117.6 million in 2026.
• Business Quant data shows CRBU's Cash & Current Investments at $117.6 million in Q1 2026, $139.3 million in Q4 2025, and $147.3 million in Q3 2025.